Cullinan Therapeutics, Inc. Share Price & Technical Analysis
CGEM · $13.84 (-1.00%)
Healthcare / Biotechnology
$13.84
-1.00%
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, …
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
6% return in May, -2% avg return in past 3 year May month.
33% return in 2026, 18% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 14% | 27% | -7% | -8% | 6% | – | – | – | – | – | – | – | 33% |
| 25 | -17% | -17% | -12% | 9% | 4% | -15% | 4% | -3% | -21% | 47% | 33% | -9% | 5% |
| 24 | 50% | 22% | -11% | 59% | -15% | -24% | 11% | 2% | -13% | -7% | -15% | -10% | 49% |
| 23 | 9% | -3% | -11% | -6% | 5% | 5% | -1% | -1% | -12% | 3% | -12% | 24% | 1% |
| 22 | -14% | 6% | -28% | -8% | 9% | 17% | 5% | 2% | -4% | 2% | -7% | -15% | -35% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$924.94M
P/E ratio
—
52W high
$16.74
52W low
$5.68
Volume
4,61,295
Beta
-0.09
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Cullinan Therapeutics, Inc. share price today?
- Cullinan Therapeutics, Inc. (CGEM) last traded around $13.84 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CGEM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CGEM. Download the app for real-time alerts.
- How can I analyze Cullinan Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.